SAP sued by o9 Solutions over alleged trade secret theft
DUBLIN - Morgan Stanley Capital Services LLC has disclosed its dealings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) securities, according to a regulatory filing submitted on November 3, 2025.
The filing, made under Rule 38.5(a) of the Irish Takeover Panel Act, reveals that on October 31, 2025, Morgan Stanley Capital Services purchased 7,756 ordinary shares of Avadel at prices ranging from $18.80 to $18.93 per share. The firm also sold 156 shares at prices between $18.89 and $19.04.
Additionally, the disclosure shows cash-settled derivative transactions involving Avadel shares. Morgan Stanley reduced a long position in contracts for difference (CFD) by 7,700 reference securities at $18.93 per unit and reduced a short position by 100 reference securities at $19.04 per unit.
The filing indicates that Morgan Stanley Capital Services is acting as a connected exempt principal trader with recognized intermediary status, dealing in a client-serving capacity in relation to Avadel Pharmaceuticals.
The disclosure was made in compliance with Irish takeover regulations that require transparent reporting of dealings by connected parties during offer periods. According to the filing, there are no indemnity arrangements, agreements, or understandings relating to options or derivatives between the disclosing party and any other person.
This information was provided in a regulatory announcement submitted to the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.